The abstract, entitled (2441) "BiovaxID Vaccine Therapy of Follicular Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial and Status of a Controlled, Randomized Phase III Trial" by C. Santos, L. Stern, L. Katz, T. Watson, and B. Gause also provides an update on the progress of the Company's ongoing Phase 3 trial. In the Phase 3 trial patients with follicular B-cell non-Hodgkin's lymphoma are being treated with BiovaxID immunotherapy following PACE [Prednisone, Doxorubicin, Cyclophosphamide, and Etoposide (ProMACE without methotrexate)] chemotherapy.
At the meeting of the American Society for Hematology, Biovest will provide an update on patients who were treated with BiovaxID in its Phase 2 clinical trial. The patients have now been followed for a median time of 9.2 years. Nine patients (45 %) remain in clinical remission at their most recent follow-up, and overall survival is 95%. Median disease free survival for the group is 96.5 months (8.04 years). To date there have been no additional reported mortalities. Additional analysis of the Phase 2 trial data will be presented by Biovest at the American Society for Hematology meeting.
The abstract reports on the progress as of August, 2005, of the ongoing Phase 3 clinical trial for this vaccine. To that date, 187 patients had been accrued onto the study. Of those patients, 145 (77.5%) achieved a CR or Cru and are being followed in this ongoing clinical trial.
Dr. Steve Arikian, CEO of Biovest International commented, "The length of the follow-up time and impressive remission data from
'"/>
Contact: Sherran Brewer
866-481-9020
SciWords
1-Dec-2005